Clinical Trial Detail

NCT ID NCT01532089
Title Erlotinib Hydrochloride With or Without Bevacizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications

lung non-small cell carcinoma

Therapies

Bevacizumab

Bevacizumab + Erlotinib

Age Groups: adult senior

No variant requirements are available.